



April 30, 2014

Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference

SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company at the Deutsche Bank 39th Annual Healthcare Conference in Boston, MA. The presentation will take place at The InterContinental Hotel on Wednesday, May 7, 2014 at 10:00 a.m. EDT.

A live webcast for the event can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. An archived replay will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases. The Company utilizes established pharmacologic modalities, including small molecules and therapeutic proteins, and well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells. The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic disorders, and a muscle satellite stem cell modulation platform, which seeks to activate the regenerative capacity of muscle for treating patients with degenerative muscle disorders. The Company is presently advancing its lead product candidate, PROHEMA[®], a pharmacologically-modulated HSC therapeutic, in Phase 2 clinical development for hematologic malignancies. Fate Therapeutics is also advancing its proprietary Wnt7a protein analogs in preclinical development for the treatment of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

CONTACT: Paul Cox, Stern Investor Relations, Inc.

212.362.1200, paul@sternir.com